Acquisition - August 2, 2019
Norwegian bioinformatics company OncoImmunity acquired by NEC
OncoImmunity will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies in […]
In a new job - June 17, 2019
Nobel Laureate joins Lytix Biopharma’s Scientific Advisory Board
The company announces the addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors. Dr James (Jim) Allison (PhD) is Regental Professor and Chair of Immunology and Executive Director of Immunotherapy at the MD Anderson Cancer Clinic, University of […]
Uncategorized - May 27, 2019
Politics Q&A: Iselin Nybø
A nationwide initiative to increase student enrollment and proficiency in the sciences, math and technology and plans for a new life sciences building at the University of Oslo are at the heart of Norway’s Ministry of Research and Higher Education’s efforts to expand the nation’s involvement and status in the life sciences. Iselin Nybø (IN), […]
Collaboration - May 12, 2019
Tromsø – An up-and-coming hub for biotech & health tech north of the Arctic Circle
Long known for its natural beauty and abundant natural resources, the City of Tromsø in Norway’s far north now is making a name for itself in medical and life sciences’ research. The world’s northernmost university, several of the Nordics’ major research institutions and a comprehensive hospital all draw researchers and professionals to Tromsø, the Nordic […]
Uncategorized - May 10, 2019
NOK 4.5 million invested in Norwegian cancer research
Radforsk, the Radium Hospital Research Foundation, is awarding several NOK 4.5 million to new research that fights cancer with light, reports Elisabeth Kirkeng Andersen, Oslo Cancer Cluster. Radforsk is an evergreen investor focusing on companies that develop cancer treatment. Since its inception in 1986, Radforsk has allocated NOK 200 million of its profit back into cancer […]
In a new job - April 9, 2019
She is the new CEO of Oslo Science City
Christine Wergeland Sørbye will lead and coordinate the development of Oslo Science City. The municipality of Oslo, the University of Oslo, Helse Sør-Øst RHF, the Oslo University Hospital HF, SINTEF and The Research Park/Oslotech will together develop the innovation district Oslo Science City, and Christine Wergeland Sørbye will now lead and coordinate this project. Oslo Science City […]
